[Clinical aspects of the excretion of alkylating cyclophosphamide metabolites in the urine of tumor bearing patients].
The urinary excretion of alkylating CP metabolites was measured in 33 tumor patients by using NPB-test under consideration of different doses, routes of administration (i.v. and i.m.) and function of the liver and the kidney. There was no limit in activation capacity with increased doses of CP. The estimation of the upper activation limit was hindered by the host's subjective toxicity. CP was activated in a comparable manner after i.v. or i.m. administration. It is of interest that liver involvement by the disease or functionally compensated post-nephrectomy state of patients investigated so far did not diminish the excretion of alkylating CP metabolites.
D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000652:urine; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000652:urine*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007668:Kidney / Q000503:physiopathology; D008099:Liver / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*
D000477:Alkylating Agents; D003520:Cyclophosphamide
Untersuchungen zur Ausscheidung alkylierender Cyclophosphamid-Metabolite im Urin von Tumorpatienten unter klinischen Aspekten.